These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 32111386)

  • 1. Evidence of Interleukin-2-Receptor-Antibody Induction in Low-Risk Living Donor Kidney Transplantation: A Single-Center Pilot Study.
    Jänigen BM; Gehrmann S; Glatz T; Seidl M; Thomusch O; Prager EP; Zschiedrich S; Fichtner-Feigl S; Pisarski P; Schneider J
    Transplant Proc; 2020 Apr; 52(3):780-784. PubMed ID: 32111386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute Rejection Rates and Graft Outcomes According to Induction Regimen among Recipients of Kidneys from Deceased Donors Treated with Tacrolimus and Mycophenolate.
    Tanriover B; Jaikaransingh V; MacConmara MP; Parekh JR; Levea SL; Ariyamuthu VK; Zhang S; Gao A; Ayvaci MUS; Sandikci B; Rajora N; Ahmed V; Lu CY; Mohan S; Vazquez MA
    Clin J Am Soc Nephrol; 2016 Sep; 11(9):1650-1661. PubMed ID: 27364616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction Therapies in Live Donor Kidney Transplantation on Tacrolimus and Mycophenolate With or Without Steroid Maintenance.
    Tanriover B; Zhang S; MacConmara M; Gao A; Sandikci B; Ayvaci MU; Mete M; Tsapepas D; Rajora N; Mohan P; Lakhia R; Lu CY; Vazquez M
    Clin J Am Soc Nephrol; 2015 Jun; 10(6):1041-9. PubMed ID: 25979971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction Therapy With ATG Compared With Anti-IL2 Basiliximab in Low-Immunologic Risk Kidney Transplant Recipients.
    Dedinská I; Graňák K; Vnučák M; Skálová P; Laca Ĺ; Krivuš J; Galajda P; Mokáň M
    Transplant Proc; 2019 Dec; 51(10):3259-3264. PubMed ID: 31732198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary pediatric live-donor-kidney transplant-recipients' outcomes by immunosuppression induction received in the United States.
    Riad S; Jackson S; Chinnakotla S; Verghese P
    Pediatr Transplant; 2021 Aug; 25(5):e13925. PubMed ID: 33333629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thymoglobulin Versus Basiliximab Induction Therapy in Low-Risk Kidney Transplant Recipients: A Single-Center Experience.
    Lee H; Lee S; Jeon JS; Kwon SH; Noh H; Han DC; Yun S; Song D
    Transplant Proc; 2018 Jun; 50(5):1285-1288. PubMed ID: 29880348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose Thymoglobulin vs Basiliximab Induction Therapy in Low-Risk Living Related Kidney Transplant Recipients: A Prospective Randomized Trial.
    Martinez-Mier G; Moreno-Ley PI; Budar-Fernández LF; Méndez-López MT; Allende-Castellanos CA; Jiménez-López LA; Barrera-Amoros DA; Aguilar-Sandoval E; De la Paz-Román M; Soto-Miranda E; Rivera-Sanchez Y; Martínez-Maldonado M
    Transplant Proc; 2021 Apr; 53(3):1005-1009. PubMed ID: 32178925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial.
    Thomusch O; Wiesener M; Opgenoorth M; Pascher A; Woitas RP; Witzke O; Jaenigen B; Rentsch M; Wolters H; Rath T; Cingöz T; Benck U; Banas B; Hugo C
    Lancet; 2016 Dec; 388(10063):3006-3016. PubMed ID: 27871759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
    Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS
    Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Basiliximab induction in patients receiving tacrolimus-based immunosuppressive regimens.
    de Sandes-Freitas TV; Felipe CR; de Franco MF; Tedesco-Silva H; Medina-Pestana JO
    Int Urol Nephrol; 2013 Apr; 45(2):537-46. PubMed ID: 23054318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Usefulness of Tacrolimus without Basiliximab in Well-Matched Living-Donor Renal Transplant Recipients in Korea.
    Baek CH; Kim JH; Yu H; Shin E; Cho H; Kim H; Yang WS; Han DJ; Park SK
    Exp Clin Transplant; 2016 Aug; 14(4):389-93. PubMed ID: 27228054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction antibody therapy in renal transplantation using early steroid withdrawal: long-term results comparing anti-IL2 receptor and anti-thymocyte globulin.
    Libório AB; Mendoza TR; Esmeraldo RM; Oliveira ML; Paes FJ; Silva Junior GB; Daher EF
    Int Immunopharmacol; 2011 Nov; 11(11):1832-6. PubMed ID: 21835269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-thymocyte globulin versus basiliximab induction in renal transplant recipients: Long-term outcome.
    Kesiraju S; Paritala P; Rao Ch UM; Athmakuri SM; Reddy VS; Sahariah S
    Saudi J Kidney Dis Transpl; 2014 Jan; 25(1):9-15. PubMed ID: 24434376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Basiliximab induction in renal transplantation: long-term outcome.
    Atlani M; Sharma RK; Gupta A
    Saudi J Kidney Dis Transpl; 2013 May; 24(3):473-9. PubMed ID: 23640617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tacrolimus, Mycophenolate Mofetil, and Low-Dose Steroids With or Without Interleukin-2 Receptor Antibody Induction Therapy: A Retrospective Cohort Analysis.
    Schwarz C; Böhmig G; Steininger R; Unger L; Kristo I; Kozakowski N; Berlakovich GA; Soliman T; Mühlbacher F
    Transplant Proc; 2015 Oct; 47(8):2446-9. PubMed ID: 26518948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison between spousal donor transplantation treated with anti-thymocyte globulin induction therapy and, living related donor transplantation treated with standard immunosuppression.
    Demir E; Paydas S; Erken U
    Saudi J Kidney Dis Transpl; 2014 May; 25(3):520-3. PubMed ID: 24821146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction therapy with thymoglobulin or interleukin-2 receptor antagonist for Chinese recipients of living donor renal transplantation: a retrospective study.
    Qiu J; Li J; Chen G; Huang G; Fu Q; Wang C; Chen L
    BMC Nephrol; 2019 Mar; 20(1):101. PubMed ID: 30902050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of thymoglobulin versus basiliximab induction therapies in living donor kidney transplant recipients with mild to moderate immunological risk - a retrospective analysis of UNOS database.
    Ali H; Mohammed M; Fülöp T; Malik S
    Ann Med; 2023 Dec; 55(1):2215536. PubMed ID: 37232582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Standard induction with basiliximab versus no induction in low immunological risk kidney transplant recipients: study protocol for a randomized controlled trial.
    Ajlan A; Aleid H; Ali TZ; Joharji H; Almeshari K; Nazmi AM; Shah Y; Devol E; Alkortas D; Alabdulkarim Z; Broering D; Alahmadi I; Ullah A; Alotaibi A; Aljedai A
    Trials; 2021 Jun; 22(1):414. PubMed ID: 34167567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.